Concepedia

Publication | Open Access

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

DOIFull Paper Access

66

Citations

16

References

2005

Year

Grace K. Dy, James P. Thomas, George Wilding, Laura M. Bruzek, Sumithra J. Mandrekar, Charles Erlichman, Dona Alberti, Kim Binger, Henry C. Pitot, Steven R. Alberts,
Clinical Cancer Research

Abstract

PS-341 given 1.5 mg/m2 twice weekly for 2 of every 3 weeks is well tolerated and should be further studied.

References

YearCitations

Page 1